Management of recurrent small cell lung cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 3, 2008, Pages 323-331

  Schneider, Bryan J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Relapse; Review; Second line chemotherapy; Small cell lung cancer; Therapeutics

Indexed keywords

AMRUBICIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PICOPLATIN; PLATINUM DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEUTROPENIA; PALLIATIVE THERAPY; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 41749087812     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0027     Document Type: Review

References (57)

1. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447.
2. Postmus PE, Berendsen HH, van Zandwijk, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after and initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987;23:1409-1411.
3. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:1697-1699.
4. Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988;21:45-48.
5. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996;14:2785-2790.
6. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
7. Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
8. Garst J, Buller R, Lane S, et al. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin Lung Cancer 2005;7:190-196.
9. Treat J, Huang CH, Lane SR, et al. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004;9:173-181.
10. Shipley DL, Hainsworth JD, Spigel DR, et al. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC) - a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2006;24(Suppl 1):384. Abstract 7083.
11. Shah C, Ready N, Perry M, et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007;57:84-88.
12. Von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-1749.
13. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared to intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-2092.
14. Dy GK, Jett JR, Geoffroy FJ, et al. Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. J Thorac Oncol 2006;1:211-217.
15. Ardizzoni A, Manegold C, Debruyne C, et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003;9:143-150.
16. Choi H, Choi B, Shin S, et al. Topotecan and etoposide as salvage chemotherapy in patients with irinotecan- and platinum-failed small-cell lung cancer: a phase II study [abstract]. J Clin Oncol 2007;25(Suppl 1):698. Abstract 18177.
17. Belvedere O, Sacco C, Ardizzoni A, et al. Second line chemotherapy with topotecan and gemcitabine in small cell lung cancer (SCLC) patients: an Alpe-Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 012) [abstract]. J Clin Oncol 2006;24(Suppl 1):668. Abstract 17014.
18. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
19. Fujita A, Takabatake H, Tagaki S, et al. [Pilot study of irinotecan in refractory small cell lung cancer.] Gan to Kgaku Ryoho 1995;22:889-893 [in Japanese].
20. Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999;22:399-402.
21. Ando M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004;44:121-127.
22. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-323.
23. Hirose T, Horichi N, Ohmori T, et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer 2003;40:333-338.
24. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998;16:3329-3334.
25. Goto K, Sekine I, Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 2004;91:659-665.
26. Fujita A, Takabatake H, Tagaki S, et al. Combination of cisplatin, ifosfamide, and irinotecan with rhG'CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology 2000;59:105-109.
27. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer a Hoosier Oncology Group study. Semin Oncol 1990;17:32-35.
28. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-1617.
29. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347-351.
30. Sonpavde G, Ansari R, Walker P, et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer. A Hoosier Oncology Group trial. Am J Clin Oncol 2000;23:68-70.
31. Agelaki S, Veslemes M, Syrigos K, et al. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 2004;43:329-333.
32. Groen H, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 1999;17:927-932.
33. Owonikoko TK, Ramalingam S, Forster J, et al. Phase II study of irinotecan and paclitaxel for patients with recurrent small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2007;25(Suppl 1):684. Abstract 18011.
34. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994;30:1058-1060.
35. Yokoyama A, Kurita Y, Watanabe K, et al. [Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel cooperative study group for lung cancer.] Gan to Kagaku Ryoho 1994;21:2609-2616 [in Japanese].
36. Masters G, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: eastern cooperative oncology group trial 1597. J Clin Oncol 2003;21:1550-1555.
37. Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003;42:97-102.
38. Schuette W, Nagel S, Juergens S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 2005;7:133-137.
39. Rocha-Lima CM, Herndon E II, Lee ME, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B study 39902. Ann Oncol 2007;18:331-337.
40. Rapti A, Agelidou A, Stergiou I, et al. Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study. Lung Cancer 2005;49:241-244.
41. Hainsworth JD, Burris HA III, Erland JB, et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2003;21:193-199.
42. Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996;53:169-172.
43. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993;29A:1720-1722.
44. Cantwell BM, Bozzino JM, Corris P, et al. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin, and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 1988;24:123-129.
45. Hanna NH, Ansari R, Bhatia S, et al. Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): a phase II study from the Hoosier Oncology Group [abstract]. J Clin Oncol 2006;24(18S):Abstract 7063.
46. Raju RN, Neubauer MA, Smith DA, et al. Pemetrexed (P) in relapsed small cell lung cancer (SCLC): preliminary results of a phase II trial [abstract]. J Clin Oncol 2007;25(Suppl 1):438. Abstract 7716.
47. Kosmas C, Tsavaris NB, Malamos NA, et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001;19:119-126.
48. Faylona EA, Loehrer PJ, Ansari R, et al. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group trial. J Clin Oncol 1995;13:1209-1214.
49. Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987;71:941-955.
50. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-lung cancer: a phase III trial of the southeastern cancer study group. J Clin Oncol 1992;10:282-291.
51. Kudoh S, Yoshimura N, Kimura T, et al. A phase II trial of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2006;24(Suppl 1):671. Abstract 17053.
52. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for the treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group study 0301. J Clin Oncol 2007;24:5448-5453.
53. Jotte RM, Reynolds CH, Conkling P, et al. A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy [abstract]. J Clin Oncol 2007;25(18S): Abstract 18064.
54. Bentzion D, Lipatov O, Polyakov I, et al. A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-ling, platinum (plat)-containing chemotherapy [abstract]. J Clin Oncol 2007;25(Suppl 1):439. Abstract 7722.
55. Mekhail T, Gettinger S, Blumenschein G, et al. A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases [abstract]. J Clin Oncol 2007;25(Suppl 1):439. Abstract 7724.
56. Stefanou D, Batistatou A, Arkoumani E, et al. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small cell and non-small-cell lung carcinoma. Histol Histopathol 2004;19:37-42.
57. Kim Y, Goto K, Yoh K, et al. Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2007;25(Suppl 1):685. Abstract 18023.